Semperit AG Holding

Earnings Release • Jul 27, 2017

Publication Date: 27.07.2017 14:38 EANS-Adhoc: Semperit AG Holding / Impairment of approx. EUR 26 million in Sempermed segment

Disclosed inside information pursuant to article 17 Market Abuse Regulation (MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Vienna - On 10 April 2017, Semperit AG Holding announced in accordance with Article 17 of the EU Market Abuse Regulation that the long-term earnings outlook for the Sempermed segment (Medical Sector) had to undergo a critical review compared with the previous assessment, which could result in a significant impairment in the Sempermed segment.

Following an in-depth review, the Management Board of Semperit AG Holding has come to the conclusion today that the sustainably achievable production volume at the site in Kamunting, Malaysia, is lower than previously assumed. As a result, an impairment of approximately EUR 26 million has to be recognised in the interim consolidated financial statements as of 30 June 2017. Thus, based on current knowledge, the goodwill of the segment will be completely impaired.

The exact amount of the impairment will be announced with the publication of the half-year financial report 2017 on 17 August 2017.

	Aussendung übermittelt durch euro adhoc
	The European Investor Relations Service